Dr. Lal PathLabs Revenue

In the fiscal year ending March 31, 2025, Dr. Lal PathLabs had annual revenue of 24.61B INR with 10.54% growth. Dr. Lal PathLabs had revenue of 6.03B in the quarter ending March 31, 2025, with 10.48% growth.

Revenue

24.61B

Revenue Growth

+10.54%

P/S Ratio

9.50

Revenue / Employee

6.00M

Employees

4,099

Market Cap

233.91B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	24.61B	2.35B	10.54%
Mar 31, 2024	22.27B	2.10B	10.40%
Mar 31, 2023	20.17B	-705.26M	-3.38%
Mar 31, 2022	20.87B	5.06B	32.01%
Mar 31, 2021	15.81B	2.51B	18.86%
Mar 31, 2020	Pro	Pro	Pro
Mar 31, 2019	Pro	Pro	Pro
Mar 31, 2018	Pro	Pro	Pro
Mar 31, 2017	Pro	Pro	Pro
Mar 31, 2016	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Sun Pharmaceutical Industries	516.03B
Divi's Laboratories	90.78B
Cipla	267.20B
Mankind Pharma	116.41B
Apollo Hospitals Enterprise	211.46B
Zydus Lifesciences	222.47B
Aurobindo Pharma	309.22B
Alkem Laboratories	127.57B

Revenue Rankings

Dr. Lal PathLabs News

18 days ago - Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY - Business Upturn
7 months ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
7 months ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
7 months ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
7 months ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
7 months ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn

More News